London (PRWEB UK) 7 May 2015
With the increase in demand for biologics in the Pharmaceutical Industry its important medicines are assessed for immunogenicity and methods to induce tolerance. SMi is pleased to announce the Immunogenicity conference, the programme will explore the latest updates on the prediction and reduction of immunogenicity, clinical results and interpretations and optimising bioassays. Through a series of interactive presentations, workshop led by selected case studies from leading drug development teams, bioanalytical experts, and academics, the programme aims to provide insight on developments necessary to deliver safe, efficacious large molecule drugs to improve the lives of patients.
Renowned industry expert David Wraith, Chief Scientific Officer and Founder from Apitope International NV will be speaking on day 1, his presentation will discuss how to switch off unwanted immune responses, focusing on the following topics; Immunogenicity is unavoidable e.g. enzyme replacement therapy; Immunological tolerance mechanisms control immune responses to self and foreign antigens; The mechanisms of tolerance induction are now being revealed: here we will discuss novel insights into tolerance induction with peptide antigens; Examples will be given from the fields of allergy, autoimmune disease and blood clotting disorders
Expert speaker panel for 2015 includes: Annie De Groot, CEO and CSO, EpiVax, Inc., Sandra Garcês, Rheumatologist Consultant and Researcher, Garcia de Orta’s Hospital, Margareta Wikén, Bioanalytical Manager, Swedish Orphan Biovitrum, Morten Nielsen, Associate Professor, The Technical University of Denmark, Gerhard Niederfellner, Head of Tumour Cell Biology, Pharma Research & Early Development, Roche Innovation Center Penzberg, Chloé Ackaert, Postdoctoral Researcher, Cellular and Molecular Immunology, Free University of Brussels and many more…
In addition to the event, there will be an interactive workshop taking place on the 1st July entitled: Tools for early immuno genicity risk assessment and reduction, hosted by Sofie Pattijn, CTO, ImmunXperts SA and Morten Nielsen, Associate Professor, Center for Biological Sequence Analysis, Technical University of Denmark. The workshop will give an overview of in silico and in vitro tools and technologies to assess and reduce immunogenicity at an early development stage. Next to the technical details and case studies, there will also be an overview of the benefits and limitations of the different tools and how to implement these into your drug development strategy.
Immunogenicity is proudly sponsored by: SQI Diagnostics
A brochure with a full list of speakers and presentations is available to download online. For further information or to book a place, visit Marriott Regents Park Hotel, London, UK
Delegate enquiries: Contact Frederick Agboletey on +44 (0)20 7827 6070 or email: fagboletey(at)smi-online(dot)co(dot)uk
2nd Annual Immunogenicity conference
29th & 30th June 2015
Marriott Regents Park Hotel, London, UK
--------------- END ---------------
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk